Exvastat Ltd, coordinator of the Impentri IMI2 consortium, announces that the first patients have been dosed in Amsterdam, NL as part of its clinical trial, evaluating Impentri™ for the treatment of critically ill patients with COVID-19 induced ARDS.

The trial is a Phase II, randomised, double-blind, placebo-controlled study being conducted at clinical centres in The Netherlands, enrolling 90 COVID-19 patients with moderate to severe ARDS and who are intubated for mechanical ventilation. This trial follows the successful completion of a Phase II study of orally administered imatinib in 386, COVID-19 infected and hospitalised patients with hypoxaemia, conducted at 10 clinical sites across The Netherlands. Details of the new trial can be found on the European Clinical Trials register [EudraCT number: 2020-005447-23].

Impentri™, a reformulation of exisiting therapy, imatinib has been developed and manufactured at KABS in Canada, and patients are initially being enrolled at the Vrije Universitat and Amsterdam Medical Centers. The trial is being managed by Simbec-Orion, based in France.

About the Consortium

The Impentri IMI2 consortium are funded by a €3.6m grant awarded by the Innovative Medicines Initiative in response to their call for coronavirus treatments, part of the European Commission’s response to the coronavirus outbreak. Exvastat are collaborating with Vrije Universitat, Amsterdam Medical Center, KABS (Canada) and Simbec-Orion to produce a reformulated version of the licensed drug, imatinib and test it in critically ill COVID-19 patients.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005142